指南与共识胸部病理细胞病理与分子病理

肺癌靶向治疗分子检测指南更新:CAP/IASLC/AMP联合发布

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
指南 / 共识 · Arch Pathol Lab Med · 2018-01-22

CONTEXT: - In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide trea…

要点

  • 所有腺癌患者应检测ROS1。
  • NGS panel应包含ERBB2、MET、BRAF、KRAS和RET。
  • EGFR抑制剂继发耐药者用5%灵敏度检测T790M。

核心结论

  • 2013年指南基本得到重申,并更新推荐允许检测细胞学样本、要求提高检测灵敏度、反对用免疫组化检测EGFR。
  • 新增推荐包括所有腺癌患者检测ROS1、NGS panel纳入ERBB2/MET/BRAF/KRAS/RET、免疫组化替代FISH检测ALK和/或ROS1、EGFR抑制剂继发耐药者用5%灵敏度检测EGFR T790M、组织有限或难获取时用游离DNA“纳入”可靶向突变。

研究设计与样本

  • 美国病理学家学会、国际肺癌研究协会和分子病理学协会召集专家小组制定循证指南,定义关键问题和文献检索词,审查摘要和全文并起草推荐。

关键数值与推荐

  • 所有腺癌患者应进行ROS1检测。
  • 进行下一代测序panel的实验室应纳入ERBB2、MET、BRAF、KRAS和RET基因。
  • 免疫组化可作为荧光原位杂交的替代方法用于ALK和/或ROS1检测。
  • EGFR抑制剂继发耐药患者应使用5%灵敏度的检测方法检测EGFR T790M突变。
  • 组织有限或难以获取时,可使用游离DNA来“纳入”可靶向突变。

临床怎么用

  • 病理科应确保检测细胞学样本的能力并提高检测灵敏度,对腺癌患者常规检测ROS1,NGS panel包含指定基因,可用免疫组化替代FISH检测ALK/ROS1,对EGFR抑制剂耐药者用高灵敏度方法检测T790M,组织不足时采用游离DNA检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: - In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. OBJECTIVE: - To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. DESIGN: - The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology convened an expert panel to develop an evidence-based guideline to help define the key questions and literature search terms, review abstracts and full articles, and draft recommendations. RESULTS: - Eighteen new recommendations were drafted. The panel also updated 3 recommendations from the 2013 guideline. CONCLUSIONS: - The 2013 guideline was largely reaffirmed with updated recommendations to allow testing of cytology samples, require improved assay sensitivity, and recommend against the use of immunohistochemistry for EGFR testing. Key new recommendations include ROS1 testing for all adenocarcinoma patients; the inclusion of additional genes ( ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018. PMID: 29355391. doi:10.5858/arpa.2017-0388-CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。